المؤلفون: Rouhard, Stéphanie, Buysschaert, Martin, Alexopoulou, Orsalia, Preumont, Vanessa

المساهمون: UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service d'endocrinologie et de nutrition

المصدر: Diabetes & metabolic syndrome, Vol. 14, no.2, p. 65-69 (2021)

مصطلحات موضوعية: Adult, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glucose, Humans, Hypoglycemia, Male, Middle Aged, Monitoring, Ambulatory, Patient Satisfaction, Prospective Studies, Quality of Life, Flash glucose monitoring, Freestyle libre, HbA1c, Satisfaction, Type 1 diabetes

الوصف: We conducted a prospective observational study to evaluate the medium-term impact of the flash glucose monitoring system (FGM) in a type 1 diabetic population. We included 248 patients, switched from conventional blood glucose monitoring (BGM) to FGM. We evaluated glycaemic control at 2-4 (T1) and 5-11 (T2) months after initiation and at the last available visit (T3, 18 ± 4 months). We asked patients to fill in, at T0 and T2, two questionnaires based on the Diabetes Treatment Satisfaction Questionnaire; and on the Hypoglycaemia Fear Survey. Glycaemic control improved, from 8.1 ± 1.3% at T0 to 7.8 ± 1.2% at T1 (p < 0.001) and remained unchanged after. Average number of controls increased from 3.2 ± 1.2 BGM to 7.7 ± 3.9 at T1 (p < 0.001). We observed a modest decrease in daily insulin doses. We evidenced an increase in mild hypoglycaemic events, especially in well-controlled subjects, but no increase of severe events. Satisfaction score improved from 30.5 ± 7.7 points to 38.3 ± 5.1 points (p = 0.018), was correlated with the reduction in and was higher in less controlled patients at inclusion. "Behaviour" score regarding hypoglycaemias decrease from 5.7 ± 4.1 to 4.4 ± 3.6 points (p < 0.001). In conclusion, this 18-months study trial indicates that using the FGM technology in patients with T1D may improve glycaemic control, in real-life conditions, especially in less controlled patients. FGM was associated with an increase of patients' satisfaction regarding treatment. Hypoglycaemic events, however, were not reduced in frequency. Therefore, the need for an educational team and a structure program in the management of this new technology remains mandatory.

العلاقة: boreal:250785; http://hdl.handle.net/2078Test.1/250785; info:pmid/31991294; urn:ISSN:1871-4021; urn:EISSN:1878-0334

الإتاحة: https://doi.org/10.1016/j.dsx.2019.12.007Test
http://hdl.handle.net/2078Test.1/250785

المؤلفون: Grimmelmann I., Momma M., Zimmer L., Hassel J. C., Heinzerling L., Pfohler C., Loquai C., Ruini C., Utikal J., Thoms K. -M., Kahler K. C., Eigentler T., Herbst R. A., Meier F., Debus D., Berking C., Kochanek C., Ugurel S., Gutzmer R.

المساهمون: Grimmelmann, I., Momma, M., Zimmer, L., Hassel, J. C., Heinzerling, L., Pfohler, C., Loquai, C., Ruini, C., Utikal, J., Thoms, K. -M., Kahler, K. C., Eigentler, T., Herbst, R. A., Meier, F., Debus, D., Berking, C., Kochanek, C., Ugurel, S., Gutzmer, R.

مصطلحات موضوعية: diabete, diabetes mellitu, immune checkpoint inhibitor, immune-related adverse event, ipilimumab, lipase, nivolumab, pancreatiti, pd-1 inhibitor, pembrolizumab, adult, aged, 80 and over, biomarker, blood glucose, type 1, exocrine pancreatic insufficiency, female, germany, human, male, melanoma, middle aged, predictive value of test, retrospective studie, skin neoplasm, time factor, treatment outcome, up-regulation, young adult

الوصف: Aim: Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods: Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results: We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of ICI resulted in decrease of lipase after reinduction of ICI lipase levels increased again in 12 of 24 patients. In 18 patients (27%), ICI was continued unchanged, and in 12 (67%) of them, lipase levels normalised. Twenty-two patients were identified with newly diagnosed type I diabetes mellitus related to ICI, and 12 (55%) thereof had also lipase elevation mainly shortly before or after the diagnosis of diabetes. Fourteen (64%) patients had other irAE, mainly thyroiditis. Irrespective of lipase elevation, patients frequently showed a rapid onset with ketoacidosis, decreased c-peptide, and strongly increased blood glucose levels. Conclusion: Increased serum lipase during ICI is often not associated with pancreatitis but with other irAE as possible cause. Therefore, it might be sufficient to regularly monitor blood glucose levels and perform further workup only in case of signs or symptoms of pancreatitis and/or exocrine pancreas insufficiency.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33812141; info:eu-repo/semantics/altIdentifier/wos/WOS:000647678000001; volume:149; firstpage:1; lastpage:10; numberofpages:10; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11573/1682141Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105295200

الإتاحة: https://doi.org/10.1016/j.ejca.2021.02.017Test
https://hdl.handle.net/11573/1682141Test

المؤلفون: Guillermo E. Umpierrez, Priyathama Vellanki

المصدر: The Lancet. Diabetes & Endocrinology

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, 2019-20 coronavirus outbreak, Time Factors, Diabetic ketoacidosis, Coronavirus disease 2019 (COVID-19), Adolescent, Databases, Factual, Endocrinology, Diabetes and Metabolism, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Diabetic Ketoacidosis, Young Adult, Endocrinology, Patient Admission, Diabetes mellitus, Pandemic, Internal Medicine, Medicine, Humans, Pandemics, Aged, business.industry, Extramural, SARS-CoV-2, Comment, COVID-19, Middle Aged, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, England, Population Surveillance, Emergency medicine, Female, business, Emergency Service, Hospital

الوصف: Diabetic ketoacidosis (DKA) has been reported to be increasing in frequency during the COVID-19 pandemic. We aimed to examine the rates of DKA hospital admissions and the patient demographics associated with DKA during the pandemic compared with in prepandemic years.Using a comprehensive, multiethnic, national dataset, the Secondary Uses Service repository, we extracted all emergency hospital admissions in England coded with DKA from March 1 to June 30, 2020 (first wave of the pandemic), July 1 to Oct 31, 2020 (post-first wave), and Nov 1, 2020, to Feb 28, 2021 (second wave), and compared these with DKA admissions in the equivalent periods in 2017-20. We also examined baseline characteristics, mortality, and trends in patients who were admitted with DKA.There were 8553 admissions coded with DKA during the first wave, 8729 during the post-first wave, and 10 235 during the second wave. Compared with preceding years, DKA admissions were 6% (95% CI 4-9; p0·0001) higher in the first wave of the pandemic (from n=8048), 6% (3-8; p0·0001) higher in the post-first wave (from n=8260), and 7% (4-9; p0·0001) higher in the second wave (from n=9610). In the first wave, DKA admissions reduced by 19% (95% CI 16-21) in those with pre-existing type 1 diabetes (from n=4965 to n=4041), increased by 41% (35-47) in those with pre-existing type 2 diabetes (from n=2010 to n=2831), and increased by 57% (48-66) in those with newly diagnosed diabetes (from n=1072 to n=1681). Compared with prepandemic, type 2 diabetes DKA admissions were similarly common in older individuals and men but were higher in those of non-White ethnicities during the first wave. The increase in newly diagnosed DKA admissions occurred across all age groups and these were significantly increased in men and people of non-White ethnicities. In the post-first wave, DKA admissions did not return to the baseline level of previous years; DKA admissions were 14% (11-17) lower in patients with type 1 diabetes (from n=5208 prepandemic to n=4491), 30% (24-36) higher in patients with type 2 diabetes (from n=2011 to n=2613), and 56% (47-66) higher in patients with newly diagnosed diabetes (from n=1041 to n=1625). During the second wave, DKA admissions were 25% (22-27) lower in patients with type 1 diabetes (from n=5769 prepandemic to n=4337), 50% (44-56) higher in patients with type 2 diabetes (from n=2608 to n=3912), and 61% (52-70) higher in patients with newly diagnosed diabetes (from n=1234 to n=1986).Our results provide evidence for differences in the numbers and characteristics of people presenting with DKA during the COVID-19 pandemic compared with in the preceding 3 years. Greater awareness of risk factors for DKA in type 2 diabetes and vigilance for newly diagnosed diabetes presenting with DKA during the COVID-19 pandemic might help mitigate the increased impact of DKA.None.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4030d612b8a51419e5090baea0f24e6Test
http://europepmc.org/articles/PMC8412797Test

المؤلفون: Assumpta Ndengeyingoma, Cécile Rousseau, Vincent Sezibera, Rose Darly Dalexis, Mireille Guerrier, Jacqueline Bukaka, Ralph Emmanuel Auguste, Kouami Adansikou, Daniel Derivois, Jude Mary Cénat, Pari-Gole Noorishad, Cyrille Kossigan Kokou-Kpolou, Lewis Ampidu Clorméus, Jean-Pierre Birangui

المصدر: Journal of Psychiatric Research

مصطلحات موضوعية: Adult, Male, Health Knowledge, Attitudes, Practice, Social stigma, media_common.quotation_subject, Short Communication, Social Stigma, Developing country, Anxiety, Stigmatization, Exposure, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Environmental health, Pandemic, Prevalence, medicine, Humans, Developing Countries, Biological Psychiatry, Low- and Middle-Income Countries, media_common, Community resilience, Resilience, business.industry, Rwanda, 1. No poverty, COVID-19, Middle Aged, Protective Factors, Resilience, Psychological, Mental health, Haiti, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Congo, Togo, Female, Health education, Psychological resilience, medicine.symptom, business, 030217 neurology & neurosurgery

الوصف: Objective Studies have documented the significant direct and indirect psychological, social, and economic consequences of the Coronavirus disease 2019 (COVID-19) in many countries but little is known on its impact in low- and middle-income countries (LMICs) already facing difficult living conditions and having vulnerable health systems that create anxiety in individuals for themselves and their loved ones. Using a multinational convenience sample from four LMICs (DR Congo, Haiti, Rwanda, and Togo), this study aims to explore the prevalence of anxiety symptoms and associated risk and protective factors during the COVID-19 pandemic. Methods A total of 1222 individuals (40.9% of women) completed a questionnaire assessing exposure and stigmatization related to COVID-19, anxiety, and resilience. Analyses were performed to examine the prevalence and predictors of anxiety. Results Findings showed a pooled prevalence of 24.3% (9.4%, 29.2%, 28.5%, and 16.5% respectively for Togo, Haiti, RDC, and Rwanda, x2=32.6, p
Highlights - Little is known on the mental health impact of the COVID-19 in low- and middle-income countries - One out of four individuals in individuals in in low- and middle-income countries reported high level of anxiety - Exposure to COVID-19, stigmatization related to COVID-19 and resilience contributed in the prediction of anxiety - Cultural strength-based mental health programs need to be developed to reinforce individual and community resilience

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c105778e0240e9a3f888ed7e0cb0093Test
http://europepmc.org/articles/PMC7527178Test

المؤلفون: S. Ashrafzadeh-Kian, M.R. Campbell, J.C. Jara Aguirre, J. Walsh, A. Kumanovics, G. Jenkinson, P. Rinaldo, M.R. Snyder, A. Algeciras-Schimnich

المصدر: Cytokine

مصطلحات موضوعية: Male, LLOQ, Lower Limit of Quantification, AMR, Analytic Measuring Range, VEGF, Vascular endothelial growth factor, G-CSF, Granulocyte colony-stimulating factor, MIP-1α, Macrophage inflammatory protein 1α, Biochemistry, Severity of Illness Index, MCP-1, Monocyte chemoattractant protein-1, Immunology and Allergy, LIF, Leukemia inhibitory factor, IL, Interleukin, vWF-A2, von Willebrand factor A2 domain, Hospital Mortality, IM, Immune Mediator, sIL-6Rα, Interleukin 6 receptor α (soluble), Immune mediator, COVID-19, Coronavirus disease 2019, Hematology, Middle Aged, Prognosis, EN-RAGE/S100A12, Extracellular newly identified receptor for advanced glycation end products binding protein, Hospitalization, C-Reactive Protein, Treatment Outcome, Multiplex assay, Area Under Curve, IL-6, Interleukin 6, Cytokines, Female, Receptors, Chemokine, Chemokines, IL-18, Interleukin 18, Adult, PDGF, Platelet-derived growth factor, CLIR, Collaborative Laboratory Integrated Reports, Immunology, Article, Fibrin Fibrinogen Degradation Products, IFNα, IFNβ, IFNγ, Interferon α, β, γ, Humans, Receptors, Cytokine, Molecular Biology, IL-6, IL-10, Interleukin 10, Interleukin-6, SARS-CoV-2, COVID-19, IP-10, CXCL-10, Interferon gamma-induced protein 10, Length of Stay, IL-1β, Interleukin 1 beta, Respiration, Artificial, SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2, ROC Curve, TNF, TNF-α, Tumor necrosis factor-alpha, Ferritins, GM-CSF, Granulocyte-macrophage colony-stimulating factor, sIL-2Rα, Interleukin 2 receptor α (soluble), Biomarkers, FGF, Fibroblast growth factor

الوصف: Background Several immune mediators (IM) including cytokines, chemokines, and their receptors have been suggested to play a role in COVID-19 pathophysiology and severity. Aim To determine if early IM profiles are predictive of clinical outcome and which of the IMs tested possess the most clinical utility. Methods A custom bead-based multiplex assay was used to measure IM concentrations in a cohort of SARS-CoV-2 PCR positive patients (n = 326) with varying disease severities as determined by hospitalization status, length of hospital stay, and survival. Patient groups were compared, and clinical utility was assessed. Correlation plots were constructed to determine if significant relationships exist between the IMs in the setting of COVID-19. Results In PCR positive SARS-CoV-2 patients, IL-6 was the best predictor of the need for hospitalization and length of stay. Additionally, MCP-1 and sIL-2Rα were moderate predictors of the need for hospitalization. Hospitalized PCR positive SARS-CoV-2 patients displayed a notable correlation between sIL-2Rα and IL-18 (Spearman’s ρ = 0.48, P=

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ea4dffd7340d4f462e705aa2180a11Test
http://europepmc.org/articles/PMC8709828Test

المؤلفون: Luca Roncati, Beatrice Lusenti

المصدر: Medical Hypotheses

مصطلحات موضوعية: 0301 basic medicine, Protein moonlighting, Male, viruses, 0302 clinical medicine, Medicine, skin and connective tissue diseases, virus diseases, General Medicine, T-helper type 1 (Th1), Middle Aged, Italy, Autopsy, Coronavirus Infections, Viral load, Cluster of differentiation 26 (CD26), Protein Binding, Adult, 2019-20 coronavirus outbreak, Th2 response, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dipeptidyl Peptidase 4, Pneumonia, Viral, Article, Coronavirus disease 19 (COVID-19), 03 medical and health sciences, Betacoronavirus, Immune system, Middle-East-respiratory-syndrome-related-coronavirus (MERS-CoV), Humans, Dipeptidyl peptidase-4 (DPP-4), Pandemics, Aged, business.industry, T-helper type 2 (Th2), SARS-CoV-2, fungi, COVID-19, Computational Biology, biochemical phenomena, metabolism, and nutrition, Th1 Cells, Severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2), 030104 developmental biology, Gene Expression Regulation, Immune System, Immunology, business, 030217 neurology & neurosurgery, T-Lymphocytes, Cytotoxic

الوصف: COVID-19 is a major public health issue around the world and new data about its etiological agent, SARS-CoV-2, are urgently necessary, also translating the scientific knowledge acquired on its more similar predecessors, SARS-CoV-1 and MERS-CoV, the coronaviruses responsible for SARS and MERS, respectively. Like SARS-CoV-1, SARS-CoV-2 exploits the ACE2 receptors to enter the host cells; nevertheless, recent bioinformatics insights suggest a potential interaction of SARS-CoV-2 with the «moonlighting protein» CD26/DPP4, exactly how MERS-CoV works. CD26/DPP4 is overexpressed on T-helper type 1 (Th1) cells and its expression increases with aging, all factors which could well explain the Th1 immune lockdown, especially in the elderly, during fatal SARS-CoV-2 infections. Facing with this scenario, it is possible that Th1 and T-cytotoxic lymphocytes are the immune cells most affected by SARS-CoV-2, and that the immune system is forced to mount a T-helper type 2 (Th2) response, the only one still mountable, in the attempt to counteract the viral load. However, in this way, the symptomatic patient experiences all the negative effects of the Th2 response, which can seriously aggravate the clinical picture.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b53ccd65919dca04d64b1a8db69b617bTest
http://europepmc.org/articles/PMC7347323Test

المؤلفون: Vincent van der Noort, Jacobus A. Burgers, Harry J.M. Groen, Jos A. Stigt, Idris Bahce, Egbert F. Smit, B. E. van den Borne, Bonne Biesma, Joachim G.J.V. Aerts, Gerarda J.M. Herder, Anne-Marie C. Dingemans, Andrew D. Vincent

المساهمون: Pulmonary Medicine, Neurosurgery, MUMC+: MA Med Staf Spec Longziekten (9), Pulmonologie, RS: N.P.I Privaatrecht niet geprog, Promovendi ODB, Family Medicine, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Pulmonary medicine, CCA - Innovative therapy

المصدر: Dingemans, A M C, Groen, H J M, Herder, G J M, Stigt, J A, Smit, E F, Bahce, I, Burgers, J A, van den Borne, B E E M, Biesma, B, Vincent, A, van der Noort, V & Aerts, JG 2015, ' A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)(aEuro) ', Annals of Oncology, vol. 26, no. 11, pp. 2286-2293 . https://doi.org/10.1093/annonc/mdv370Test
Annals of Oncology, 26(11), 2286-2293. Elsevier Ltd.
Annals of Oncology, 26(11), 2286-2293. Oxford University Press

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Paclitaxel, Urology, VINORELBINE, Phases of clinical research, bevacizumab, Vinorelbine, DONOR, THERAPY, Carboplatin, chemistry.chemical_compound, CISPLATIN, SDG 3 - Good Health and Well-being, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Lung cancer, Aged, Neoplasm Staging, Cisplatin, Aged, 80 and over, NITRIC-OXIDE, business.industry, Hazard ratio, Area under the curve, nonsmall-cell lung cancer, Hematology, Middle Aged, medicine.disease, VEGF, nitroglycerin, Oncology, chemistry, Anesthesia, Female, Hypoxia-Inducible Factor 1, business, medicine.drug

الوصف: Background: Nitroglycerin ( NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia- inducible- factor ( HIF)- 1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/ cisplatin in patients with advanced nonsmall- cell lung cancer ( NSCLC). In addition, there is evidence that the combination of bevacizumab and HIF- 1 inhibitors increases antitumor activity. Patients and methods: In this randomized phase II trial, chemo- naive patients with stage IV nonsquamous NSCLC were randomized to four cycles of carboplatin ( area under the curve 6)- paclitaxel ( 200 mg/ m2)- bevacizumab 15 mg/ kg on day 1 every 3 weeks with or without NTG patches 15 mg ( day - 2 to + 2) followed by bevacizumab with or without NTG until progression. Response was assessed every two cycles. Primary end point was progression- free survival ( PFS). The study was powered ( 80%) to detect a decrease in the hazard of tumor progression of 33% at a = 0.05 with a two- sided log- rank test when 222 patients were enrolled and followed until 195 events were observed. Results: Between 1 January 2011 and 1 January 2013, a total of 223 patients were randomized; 112 control arm and 111 experimental arm; response rate was 54% in control arm and 38% in experimental arm. Median [ 95% confidence interval ( CI)] PFS in control arm was 6.8 months ( 5.6- 7.3) and 5.1 months ( 4.2- 5.8) in experimental arm, hazard ratio ( HR) 1.27 ( 95% CI 0.96- 1.67). Overall survival ( OS) was 11.6 months ( 8.8- 13.6) in control arm and 9.4 months ( 7.8- 11.3) in experimental arm, HR 1.02 ( 95% CI 0.71- 1.46). In the experimental arm, no additional toxicity was observed except headache ( 6% versus 52% in patients treated with NTG). Conclusion: Adding NTG to first- line carboplatin- paclitaxel- bevacizumab did not improve PFS and OS in patients with stage IV nonsquamous NSCLC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce79aa82e47a39fa2e0aaa7862cfa29Test
https://doi.org/10.1093/annonc/mdv370Test

المؤلفون: Mariana T. Cerqueira, Rogério P. Pirraco, Alexandra P. Marques, Belém Sampaio-Marques, M. Costa, Rui L. Reis, Paula Ludovico, Tírcia C. Santos

المساهمون: Universidade do Minho

المصدر: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Pathology, medicine.medical_specialty, Stromal vascular fraction, Biomedical Engineering, Adipose tissue, Neovascularization, Physiologic, Biology, Biochemistry, Biomaterials, 03 medical and health sciences, Mice, 0302 clinical medicine, medicine, Animals, Humans, Hypoxia, Molecular Biology, Cell sheet, Cells, Cultured, Science & Technology, Tissue Engineering, European research, Vascularization, Endothelial Cells, General Medicine, Hypoxia-Inducible Factor 1, alpha Subunit, Cell Hypoxia, 030104 developmental biology, Adipose Tissue, 030220 oncology & carcinogenesis, Immunology, Heterografts, Female, Cell sheet engineering, SVF, Biotechnology

الوصف: Current vascularization strategies for Tissue Engineering constructs, in particular cell sheet-based, are limited by time-consuming and expensive endothelial cell isolation and/or by the complexity of using extrinsic growth factors. Herein, we propose an alternative strategy using angiogenic cell sheets (CS) obtained from the stromal vascular fraction (SVF) of adipose tissue that can be incorporated into more complex constructs. Cells from the SVF were cultured in normoxic and hypoxic conditions for up to 8 days in the absence of extrinsic growth factors. Immunocytochemistry against CD31 and CD146 revealed spontaneous organization in capillary-like structures, more complex after hypoxic conditioning. Inhibition of HIF-1α pathway hindered capillary-like structure formation in SVF cells cultured in hypoxia, suggesting a role of HIF-1α. Moreover, hypoxic SVF cells showed a trend for increased secretion of angiogenic factors, which was reflected in increased network formation by endothelial cells cultured on matrigel using that conditioned medium. In vivo implantation of SVF CS in a mouse hind limb ischemia model revealed that hypoxia-conditioned CS led to improved restoration of blood flow. Both in vitro and in vivo data suggest that SVF CS can be used as simple and cost-efficient tools to promote functional vascularization of TE constructs.
R.P. Pirraco contract financed by SFRH/BPD/101886/2014. B.S. Marques contract financed by SFRH/BPD/90533/2012. M.T. Cerqueira contract financed by SFRH/BPD/96611/2013. T.C. Santos contract financed by SFRH/BPD/101952/2014. Financial support by RL3-TECT-NORTE-01-0124-FEDER-000020 and the European Research Council Advanced Grant (ERC-2012-AdG_20120216- 321266) for the project ComplexiTE is also acknowledged.
info:eu-repo/semantics/publishedVersion

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b90a4c5658578e08f2e6ce8685087c5Test

المؤلفون: Ichiro Kawachi, Mauricio Avendano, Carlos Riumallo-Herl

المساهمون: Epidemiology

المصدر: Social Science & Medicine
Social Science & Medicine, 105, 47-58. Elsevier Ltd.

مصطلحات موضوعية: Adult, Male, Health (social science), Developing country, Disease, Trust, Article, Social support, History and Philosophy of Science, SDG 3 - Good Health and Well-being, Diabetes Mellitus, Humans, Social determinants of health, Chile, Socioeconomics, Developing Countries, Aged, Aged, 80 and over, Depression, 1. No poverty, Social Support, Welfare state, Health Status Disparities, Middle Aged, Social mobility, Mental health, Health Surveys, 3. Good health, Hypertension, Demographic economics, Female, Psychology, Biomarkers, Social capital

الوصف: In high-income countries, higher social capital is associated with better health. However, there is little evidence of this association in low- and middle-income countries. We examine the association between social capital (social support and trust) and both self-rated and biologically assessed health outcomes in Chile, a middle-income country that experienced a major political transformation and welfare state expansion in the last two decades. Based on data from the Chilean National Health Survey (2009-10), we modeled self-rated health, depression, measured diabetes and hypertension as a function of social capital indicators, controlling for socio-economic status and health behavior. We used an instrumental variable approach to examine whether social capital was causally associated with health. We find that correlations between social capital and health observed in high-income countries are also observed in Chile. All social capital indicators are significantly associated with depression at all ages, and at least one social capital indicator is associated with self-rated health, hypertension and diabetes at ages 45 and above. Instrumental variable models suggest that associations for depression may reflect a causal effect from social capital indicators on mental well-being. Using aggregate social capital as instrument, we also find evidence that social capital may be causally associated with hypertension and diabetes, early markers of cardiovascular risk. Our findings highlight the potential role of social capital in the prevention of depression and early cardiovascular disease in middle-income countries.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f690832864adc5ae86fee51357bb5bTest
https://pure.eur.nl/en/publications/08701d54-f98d-4133-b76d-27fd0a882ecdTest

المؤلفون: Dirk J. Ruiter, Danielle Lienard, Ulrich Keilholz, Izabella Jagiello, Wim H. J. Kruit, Gerard Groenewegen, Wlodzimierz Ruka, Michelle Delauney, François Sales, Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Rona M. MacKie, Cornelis J. A. Punt, Konstantin Stoitchkov

المساهمون: Surgery, Medical Oncology, Other departments

المصدر: The Lancet (London), 366, 1189-96
Lancet (UK), 366(9492), 1189-1196. Elsevier Ltd.
The Lancet (London), 366, 9492, pp. 1189-96
Lancet, 366(9492), 1189-1196. Elsevier Limited

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Skin Neoplasms, Alpha interferon, Antineoplastic Agents, Interferon alpha-2, Neuroinformatics [DCN 3], Gastroenterology, law.invention, Randomized controlled trial, Immune Regulation [NCMLS 2], Translational research [ONCOL 3], law, Internal medicine, medicine, Adjuvant therapy, Clinical endpoint, Humans, Melanoma, Interferon alfa, Aged, Intention-to-treat analysis, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, Hazard ratio, Interferon-alpha, Immunotherapy, gene therapy and transplantation [UMCN 1.4], General Medicine, Middle Aged, Combined Modality Therapy, Recombinant Proteins, Surgery, Chemotherapy, Adjuvant, Lymphatic Metastasis, Toxicity, Female, business, Functional Neurogenomics [DCN 2], medicine.drug

الوصف: Contains fulltext : 49192.pdf (Publisher’s version ) (Closed access) BACKGROUND: Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 years. High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consistent effect on disease free survival, but not on overall survival, and the latter no consistent effect on either. Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients. METHODS: We did a randomised controlled trial in 1388 patients who had had a thick primary tumour (thickness > or = 4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) and had been assigned to 13-months (n=553) or 25 months (n=556) of treatment with subcutaneous interferon alfa 2b, or observation (n=279). Treatment comprised 4 weeks of 10 million units (MU) of interferon alfa (5 days per week) followed by either 10 MU three times a week for 1 year or 5 MU three times a week for 2 years, to a total dose of 1760 MU. Our primary endpoint was DMFI. Analyses were by intent to treat. FINDINGS: After a median follow-up of 4.65 years, we had recorded 760 distant metastases and 681 deaths. At 4.5 years, the 25-month interferon group showed a 7.2% increase in rate of DMFI (hazard ratio 0.83, 97.5% CI 0.66-1.03) and a 5.4% improvement in overall survival. The 13-month interferon group showed a 3.2% increase in rate of DMFI at 4.5 years (0.93, 0.75-1.16) and no extension of overall survival. Toxicity was acceptable, with 18% (195 of 1076) of patients going off study because of toxicity or as a result of refusal of treatment because of side-effects. INTERPRETATION: Interferon alfa as used in the regimens studied does not improve outcome for patients with stage IIb/III melanomas, and cannot be recommended. With respect to efficacy of the drug, duration of treatment seemed more important than dose, and should be assessed in future trials.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3018d280246861bd7a28783df0b72ebTest
https://doi.org/10.1016/S0140-6736Test(05)67482-X